New Delhi, Delhi, India:
Elekta pronounces that Karkinos Healthcare, a number one healthcare supplier in India, will purchase greater than ten linear accelerator (linac) techniques to be strategically deployed throughout the nation. The firms share the ambition to enhance affected person accessibility to superior precision most cancers remedy.
The deal will embody a number of Elekta Versa HD linacs, which is designed to deal with a spectrum of tumors all through the physique supporting each standard and extremely subtle strategies, in addition to numerous Elekta Harmony Pro techniques, the corporate’s most efficient linac but, designed to present the very best in-room expertise for each sufferers and healthcare professionals.
Although an estimated 2.7 million individuals in India reside with most cancers1 – with a 12 p.c enhance by 20252 – firms akin to Karkinos Healthcare and Elekta are offering hope. Last yr, Elekta introduced its ACCESS 2025 technique to make radiotherapy accessible to 300 million extra individuals in underserved markets by 2025.
Manikandan Bala, Elekta’s Managing Director for India, stated, “The continuous rise of India’s cancer burden means that access to advanced cancer care technology remains a concerning public health challenge. Elekta’s collaboration with Karkinos Healthcare is a step towards strategically identifying these gaps and addressing such challenges. Through our synergies, we look forward to transforming the current cancer care landscape by increasing patient access to state-of-the-art precision radiotherapy solutions throughout India.”
R. Venkataramanan, Founder & Chief Executive Officer, Karkinos Healthcare Pvt. Ltd, added, “Cancer services in India have always seen a geographic skew towards big cities and southern India. We hope to play a small catalytic part in bringing greater equity in radiotherapy through our collaboration with Elekta, combining our strengths in technology and clinical expertise. With barely ten percent of the desired radiotherapy capacity as per the recommendations of the World Health Organization in India, radiotherapy access has been a key area of focus for Karkinos.”
1 Cancer Statistics – India Against Cancer
2 ICMR-NCDIR National Cancer Registry Programme estimates 12% enhance in most cancers instances within the nation by 2025 (press launch)
About Elekta
As a frontrunner in precision radiation remedy, Elekta is dedicated to making certain each affected person has entry to the very best most cancers care attainable. We brazenly collaborate with clients to advance sustainable, outcome-driven and cost-efficient options to meet evolving affected person wants, enhance lives and carry hope to everybody coping with most cancers. To us, it is private, and our world group of 4,700 staff combines ardour, science, and creativeness to profoundly change most cancers care. We don’t simply construct expertise, we construct hope. Elekta is headquartered in Stockholm, Sweden, with workplaces in additional than 40 nations and listed on Nasdaq Stockholm. For extra data, go to elekta.com or observe @Elekta on Twitter.
Click right here for Media Contact Details
Mattias Thorsson (Vice President, Head of Corporate Communications), Elekta, [email protected], +46 70 865 8012
Raven Canzeri (Global Director, Media Relations), Elekta, [email protected], +1 770-670-2524
Karan Mehrotra (Marketing and Communications Manager, Media Relations), Elekta, [email protected], +91-9632094499
Submit your press launch
